Welcome to our dedicated page for PetVivo Holdings SEC filings (Ticker: PETV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PetVivo Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PetVivo Holdings's regulatory disclosures and financial reporting.
PetVivo Holdings has signed an Agreement and Plan of Merger to acquire PiezoBioMembrane, Inc. (PBM) in an all‑stock transaction. PBM will merge into a PetVivo subsidiary and, after closing, operate as a wholly owned subsidiary of Cosmeta Corp., PetVivo’s biomaterials-focused operating arm.
PBM shareholders are slated to receive an aggregate of 3,000,000 shares of PetVivo restricted common stock. A first block of up to 1,500,000 shares will be fully vested at closing, while the remaining “Milestone Shares” will be issued but subject to forfeiture unless specified development and regulatory milestones are achieved.
Before closing, PBM must clear defined liabilities and convert or settle all preferred stock, SAFEs, options, warrants and other securities. Closing also depends on PetVivo completing an equity financing with at least $5.0 million in gross proceeds. PBM’s extensive intellectual property portfolio will remain in PBM, and key PBM personnel are expected to stay involved through consulting and service arrangements.
PetVivo Holdings, Inc. major holder A.L. Sarroff Fund, LLC reported open-market purchases tied to unit financing. The fund bought 187,500 shares of Common Stock and 187,500 Warrants, with each Unit priced at $0.80 and consisting of one share plus one Warrant.
The Warrants allow purchase of 187,500 shares of Common Stock at an exercise price of $1.10 per share until June 9, 2036. Following the transactions, the fund holds 10,439,729 shares of Common Stock and 187,500 Warrants directly, indicating a modest incremental increase in its position.
PetVivo Holdings, Inc. received gross proceeds of $150,000 on June 8, 2026 from a partial exercise of an investor purchase option under a March 13, 2026 Subscription Agreement, bringing total equity financing in this unit Offering to $1,150,000.
The company has now issued 1,437,500 Units at $0.80 per Unit, including 187,500 Units in the latest tranche. Each Unit includes one common share and a warrant to buy one common share at $1.10 per share, exercisable immediately and expiring three years from issuance.
Earlier installments provided $400,000 on March 13, 2026 for 500,000 Units and $600,000 on April 15, 2026 for 750,000 Units. The investor may still purchase up to an additional $1,350,000 of Units, or 1,687,500 Units, through July 15, 2026 on substantially the same terms.
A.L. Sarroff Fund, LLC, a 10% owner of PetVivo Holdings, Inc., reported a bona fide gift transfer of 200,000 shares of common stock on May 28, 2026. The transfer was recorded at $0.00 per share, and the fund now directly holds 10,252,229 shares. Alan L. Sarroff, as Chief Executive Officer and Managing Member of the fund, is deemed to beneficially own these securities with sole voting and dispositive power.
PetVivo Holdings, Inc. saw its significant shareholder A.L. Sarroff Fund, LLC make an open-market purchase of common stock. On May 22, 2026, the fund bought 250,000 shares at 0.40 per share, increasing its direct holdings to 10,452,229 shares.
Alan L. Sarroff, as Chief Executive Officer and Managing Member of A.L. Sarroff Fund, is deemed to beneficially own these securities and to have sole voting and dispositive power over them. This transaction modestly increases an already large position in the company.
PetVivo Holdings, Inc. reported that its Chief Financial Officer, Garry N. Lowenthal, indirectly acquired 66,421 shares of common stock as a grant of restricted stock. The award was made to a corporation owned by him as compensation for his past performance at an implied price of $0.72 per share.
Following this grant, the filing shows 878,881 shares of common stock held indirectly through the corporation. This is a compensation-related, non-market transaction rather than an open-market purchase or sale.
Lai John reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. reported that a corporation owned by Chief Executive Officer John Lai received a grant of restricted common stock as compensation for his past performance. The award covers 66,421 shares of common stock at a stated value of $0.72 per share.
Following this grant, the corporation associated with Lai holds 2,306,913 shares of PetVivo common stock indirectly. This is a compensation-related stock award rather than an open-market purchase or sale, and reflects additional equity granted to an entity affiliated with the CEO.
Rudelius Robert James reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings director Robert James Rudelius purchased 50,000 shares of restricted common stock in a private sale. On April 15, 2026, he bought these shares from another PetVivo shareholder at $0.40 per share, bringing his direct holdings to 403,392 common shares. He also reports indirect ownership of 21,000 common shares held by a corporation.
PetVivo Holdings, Inc. closed the final tranche of a private equity financing on April 15, 2026, receiving $600,000 and bringing the total investment under a Subscription Agreement to $1,000,000. The Company issued 1,250,000 units at $0.80 per unit, each unit containing one restricted common share and a warrant to buy one common share at $1.10. The warrants are exercisable immediately and expire three years from issuance. The investor also received an option to purchase up to an additional $1,500,000 of equity on similar terms, for up to 1,875,000 more units, which the Company anticipates could be funded on or before June 15, 2026. The transaction was structured as a private placement to an accredited investor under Section 4(a)(2) and Regulation D, and all securities issued are characterized as restricted.
PetVivo Holdings, Inc. entered into a Subscription Agreement for $1,000,000 of equity financing through 1,250,000 units priced at $0.80 per unit. Each unit includes one restricted common share and a warrant to buy one share at $1.10, exercisable immediately and expiring three years from issuance.
The company received $400,000 on March 13, 2026 and expects the remaining $600,000 by April 15, 2026. The investor also received an option to provide an additional $1,500,000 for 1,875,000 more units on the same terms, anticipated by June 30, 2026. The private placement was conducted under Section 4(a)(2) and Regulation D, with the investor representing accredited status, and all securities issued as restricted under Rule 144.